Glycoprl-F Dpicaps is a combination bronchodilator formulation containing Formoterol (6 mcg) and Glycopyrrolate (25 mcg), indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and related respiratory conditions characterized by airflow obstruction. Formoterol, a long-acting beta2-adrenergic receptor agonist (LABA), facilitates bronchodilation by relaxing bronchial smooth muscle, thereby improving airflow and reducing symptoms such as dyspnea and wheezing. Glycopyrrolate, a long-acting muscarinic antagonist (LAMA), complements this effect by inhibiting acetylcholine-mediated bronchoconstriction, further enhancing airway patency. The dual mechanism of action provides sustained bronchodilation, improving lung function, exercise tolerance, and quality of life in patients with moderate to severe COPD. Glycoprl-F Dpicaps is administered via inhalation, ensuring targeted delivery to the respiratory tract with a rapid onset of action and prolonged duration, allowing twice-daily dosing. It is essential to use this medication as prescribed, avoiding abrupt discontinuation to prevent exacerbations. Common adverse effects may include dry mouth, headache, and tremors; however, serious side effects are rare when used appropriately. Glycoprl-F Dpicaps should be used with caution in patients with cardiovascular disorders, glaucoma, or urinary retention. Regular monitoring and adherence to therapy optimize therapeutic outcomes.